Beta
365693

TARGETING WNT PATHWAY THROUGH miR-142-3P AS A POTENTIAL THERAPEUTIC APPROACH IN ORAL SQUAMOUS CELL CARCINOMA (IN VITRO STUDY)

Article

Last updated: 30 Dec 2024

Subjects

-

Tags

Oral pathology

Abstract

Introduction: Oral squamous cell carcinoma (OSCC) accounts for 95% of oral cancers and is associated with a low 5-year survival rate using the conventional treatments methods. Advancements in oncological research require understanding the molecular mechanisms driving OSCC occurrence and progression to devise more effective therapeutic approaches and improving prognostic outcomes. Among these mechanisms, the WNT/β-catenin signaling pathway is recognized for its contribution in promoting tumorigenesis, cancer progression, and metastasis, making it a potential target for unconventional cancer therapies. MicroRNA-142-3p (miR-142-3p), a constituent of the miR-142 family, has demonstrated tumor-suppressive properties in certain malignancies. It was proposed that miR-142-3p positively modulates WNT signaling by directly targeting the adenomatous polyposis coli (APC) gene. This targeting destabilizes β-catenin, resulting in suppression of WNT pathway activity.
Objectives: In this current investigation, the aim was to explore the capabilities of miR-142-3p in modulating the WNT pathway and evaluating its impact on the proliferation, migration, and apoptosis of OSCC-4 cells.
Methodology: MiR-142-3p was transfected into OSCC-4 cell line. MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay was employed to determine cytotoxicity, while the impact on cell migration was evaluated through scratch wound healing test. Apoptotic effects were evaluated using Annexin-V, while cell proliferation was measured through Ki-67 staining, both analyzed by flow cytometry.
Results: The results indicated that miR-142-3p suppressed OSCC-4 proliferation and migration, demonstrating its anti-proliferative potential. It didn't induce early apoptosis however, it enhanced late-stage apoptosis in a dose-dependent manner.
Conclusions: miR-142-3p exhibits a promise as a potential therapeutic option for OSCCs.

DOI

10.21608/adjalexu.2024.245158.1428

Keywords

Oral squamous cell carcinoma, Wnt pathway, epithelial mesenchymal transition, miR-142-3p

Authors

First Name

Yara

Last Name

Eldahshan

MiddleName

Moustafa

Affiliation

Oral Pathology Department, Faculty of Dentistry, Alexandria University, Alexandria, Egypt

Email

yara.eldahshan92@gmail.com

City

Alexandria

Orcid

-

First Name

Sahar

Last Name

Riad

MiddleName

Emad

Affiliation

Oral Pathology Department, Faculty of Dentistry, Alexandria University, Alexandria, Egypt

Email

saharriad7@yahoo.com

City

Alexandria

Orcid

-

First Name

Hagar

Last Name

Elkafrawy

MiddleName

Ramadan

Affiliation

Medical Biochemistry Department, Center of Excellence for Research in Regenerative Medicine and Applications (CERRMA), Faculty of Medicine, Alexandria University, Egypt

Email

hagar.elkafrawy@alexmd.edu.eg

City

Alexandria

Orcid

-

First Name

Enas

Last Name

Magdy

MiddleName

Omar

Affiliation

Oral Pathology Department, Faculty of Dentistry, Alexandria University, Alexandria, Egypt

Email

inas.magdy@gmail.com

City

Alexadria

Orcid

-

First Name

Mai

Last Name

Saleh

MiddleName

Mahmoud

Affiliation

Oral Pathology Department, Faculty of Dentistry, Alexandria University, Alexandria, Egypt

Email

dr.mai.mohmoud@gmail.com

City

Alexandria

Orcid

-

Related Issue

-2

Receive Date

2023-10-28

Publish Date

2024-07-08

Print ISSN

1110-015X

Online ISSN

2536-9156

Link

https://adjalexu.journals.ekb.eg/article_365693.html

Detail API

https://adjalexu.journals.ekb.eg/service?article_code=365693

Order

13

Type

Original Article

Type Code

1,057

Publication Type

Journal

Publication Title

Alexandria Dental Journal

Publication Link

https://adjalexu.journals.ekb.eg/

MainTitle

TARGETING WNT PATHWAY THROUGH miR-142-3P AS A POTENTIAL THERAPEUTIC APPROACH IN ORAL SQUAMOUS CELL CARCINOMA (IN VITRO STUDY)

Details

Type

Article

Created At

30 Dec 2024